* Fulgent Genetics Inc FLGT.OQ reported quarterly adjusted
earnings of 31 cents per share for the quarter ended September
30, higher than the same quarter last year, when the company
reported EPS of -39 cents. The mean expectation of
three analysts for the quarter was for a loss of 15 cents per
share. Wall Street expected results to range from -19 cents
to -9 cents per share.
* Revenue fell 15.3% to $71.74 million from a year ago;
analysts
expected $71.72 million.
* Fulgent Genetics Inc's reported EPS for the quarter was a
loss
of 48 cents.
* The company reported a quarterly loss of $14.65 million.
* Fulgent Genetics Inc shares had risen by 1.3% this
quarter and
lost 23.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the healthcare
facilities & services peer group is also "hold"
Wall Street's median 12-month price target for Fulgent Genetics
Inc is 27.00
This summary was machine generated from LSEG data November 8 at
04:21 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.15 0.31 Beat
Jun. 30 2024 -0.30 0.15 Beat
Mar. 31 2024 -0.32 -0.01 Beat
Dec. 31 2023 -0.29 0.28 Beat